Vertex Pharmaceuticals VRTX Payment for (Proceeds from) Other Investing Activity
Payment for (Proceeds from) Other Investing Activity at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForProceedsFromOtherInvestingActivities.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's payment for (proceeds from) other investing activity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's payment for (proceeds from) other investing activity?
- Vertex Pharmaceuticals (VRTX) reported payment for (proceeds from) other investing activity of $0 in Q1 2026.
- How has Vertex Pharmaceuticals's payment for (proceeds from) other investing activity changed year-over-year?
- Vertex Pharmaceuticals's payment for (proceeds from) other investing activity decreased by 100.0% year-over-year, from $5.3M to $0.
- What is the long-term trend for Vertex Pharmaceuticals's payment for (proceeds from) other investing activity?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's payment for (proceeds from) other investing activity has grown at a -18.9% compound annual growth rate (CAGR), from $47.8M to $25.5M.
- What does payment for (proceeds from) other investing activity mean?
- Net cash flows resulting from investing activities that do not fall under standard categories like securities or loans. This may include investments in joint ventures, real estate, or other non-financial assets. It serves as a catch-all for miscellaneous capital deployment or divestment activities.